Qiagen marks milestone for TB blood test

LabPulse.com staff writers
Mar 23, 2022
2019 12 03 00 00 5470 Tuberculosis Lungs 400

Qiagen's QuantiFeron blood test has been used to screen patients for tuberculosis (TB) infection more than 100 million times since its launch, the company said as it marks World TB Day.

The fourth-generation QuantiFeronTB Gold Plus assay is being used to test patients in over 130 countries, the company said. It identifies interferon-gamma released by T cells after recognizing TB-specific antigens as a marker of TB infection.

The U.S. Food and Drug Administration in December 2021 removed limitations following data review for testing patients with weakened immune systems, pregnant women, and children.

The company is also working with partners to provide additional automation options to reach more patients and increase the number of diseases that the blood test can be used for, including SARS-CoV-2 and Lyme disease.

Latest in Immune System Diseases
Business Graph Money Stocks Social
AbbVie to buy Landos Biopharma for up to $212M
March 25, 2024
2022 09 23 14 44 4203 Crispr Tiles 400
CRISPR may enable rapid, sensitive test for COVID-19
September 26, 2022
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
2022 09 09 16 29 7140 Computer Head 400
Lunaphore, Nucleai to provide AI-based spatial biology analysis
September 8, 2022
Related Stories
2020 04 23 00 03 7623 Lung General 400
Infectious
PerkinElmer gets FDA approval for kit to automate TB test
2020 07 07 21 02 7380 Parkinsons Definition 400
Biomarker Discovery & Validation
Qiagen, Neuron23 to develop CDx for Parkinson’s
2022 07 13 19 56 4243 3 D Monkeypox Infecting Cell 400
Enterovirus
Qiagen launches syndromic monkeypox test for research
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Immune System Diseases
AbbVie to buy Landos Biopharma for up to $212M
By LabPulse.com staff writers
AbbVie has announced that it will buy drug developer Landos Biopharma in a deal worth up to $212 million. The deal will expand Abbvie’s portfolio, especially in the arena of immune system-related illnesses.
March 25, 2024
Business Graph Money Stocks Social
CRISPR may enable rapid, sensitive test for COVID-19
By Joseph Constance
The device has the potential for use as a diagnostic test at the point of care (POC), according to its developers.
September 26, 2022
2022 09 23 14 44 4203 Crispr Tiles 400
N-antigen levels point to COVID severity in NIH study
By Jared Berberabe
The study by researchers at the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) was a cross-sectional follow-up analysis involving 2,540 participants who had been previously enrolled in the Therapeutics for Inpatients with COVID-19 (TICO) platform trial.
September 8, 2022
2020 03 18 20 13 7386 Virus Coronavirus Covid 19 400
Lunaphore, Nucleai to provide AI-based spatial biology analysis
By LabPulse.com staff writers
Combining Lunaphore's Comet hyperplex staining and imaging platform, a fully automated sequential immunofluorescence (seqIF) instrument, with Nucleai's Atom artificial-intelligence (AI) spatial biology platform will enable the companies to generate new insights from tissue biopsies and provide labs with an integrated end-to-end spatial biology workflow.
September 8, 2022
2022 09 09 16 29 7140 Computer Head 400
Week in Review: Room-temperature CRISPR, Roche T-cell test for COVID response, Qiagen monkeypox syndromic panel, and more
By Leo O'Connor
Dear LabPulse.com member,
August 17, 2022
'Rogue antibodies' hint at severe COVID risk
By Leah Sherwood
The goal of the study was to identify circulating factors, such as hormones and antibodies, in COVID-19 patients that contribute to the activation and dysfunction of endothelial cells, which are the main type of cell found in the inside lining of blood vessels, lymph vessels, and the heart.
February 16, 2022
2020 05 05 20 17 1261 Sars Co V 2 Antibodies 400
AMP 2021 meeting puts spotlight back on cancer
By Bruce Carlson
Seminars at AMP 2021 focused on technologies and techniques to help detect and profile tumors, with special emphasis on hard-to-detect cancer cells that remain in patients after treatment.
November 22, 2021
2021 11 23 00 25 3048 Lab Analyzer Automation 400
Qiagen debuts solution for SARS-CoV-2 T-cell research
By LabPulse.com staff writers
QuantiFeron SARS-CoV-2 ROU is a modular system based on the platform Qiagen developed for its QuantiFeron-TB Gold Plus test for latent tuberculosis.
December 6, 2020
2019 11 19 19 30 0103 T Cell 400
Vaccines won't eliminate the need for COVID-19 testing
By Bruce Carlson
It may be natural to suspect that if a vaccine is available, there will be fewer cases thus less reason to test. But this isn't normally the interplay between vaccines and diseases.
November 23, 2020
2020 11 19 03 54 0444 Senior Swab Test 400
Who should get the 1st COVID-19 vaccines?
By Leah Sherwood
Current strategic prioritization plans emphasize the importance of vaccinating healthcare workers, since doing so preserves the healthcare system itself. Another priority is to directly protect the elderly and people with comorbidities, who are at the highest risk of death or hospitalization from COVID-19.
October 25, 2020
2020 10 24 00 06 5467 Viral Like Particles Vaccine 400
Interleukin-6 testing grows rapidly, with limited evidence of utility
By David Grenache, PhD
Cytokines are small proteins released by many different types of cells, including the white blood cells of the immune system. Cytokines help regulate the immune system's response to an infection and cause inflammation. The storm happens when the release of cytokines goes into an uncontrolled overdrive causing hyperinflammation which damages the body's organs. In the lungs, this inflammation causes fluid to accumulate in the airspaces which then leads to ARDS.
June 8, 2020
2020 02 04 22 50 3305 Lab Pulse Second Opinion Logo Circlev2
Sequencing seeks to stay ahead of new COVID-19 surges
By Alice Kan
Sequencing has been an essential tool for the development of strategies and therapeutics in the fight against COVID-19, and sequencing-based rapid and high-throughput diagnostics for COVID-19 are in development. Sequencing technology suppliers are collaborating with researchers to develop sequencing-based diagnostic tools. For example, several groups are using Illumina's next-generation sequencing (NGS) technology to develop ultrahigh-throughput COVID-19 diagnostic testing.
June 7, 2020
2019 10 31 20 41 2019 Dna Man Woman 400
Page 1 of 3
Next Page